Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

Conditions

Blood draw for the laboratory assessment — DIAGNOSTIC_TEST
Blood will be drawn up to every cycle during neoadjuvant treatment
Neoadjuvant treatment — DRUG
Given by IV

To learn about changes in ctDNA during the diagnosis, treatment, and post-treatment surveillance of EBC.

Arm: Arm A
Participants in Arm A are receiving neoadjuvant therapy (treatment before breast surgery)
Arm: Arm B
Participants in Arm B have early-stage triple negative breast cancer (TNBC) or HER2-positve (HER2+) breast cancer.
Arm: Arm C
Participants in Arm C are receiving adjuvant therapy (treatment after breast surgery) with a CDK4/6-inhibitor (such as abemaciclib or ribociclib).
Arm: Arm D
Participants in Arm D are receiving adjuvant therapy with a PARPinhibitor (such as olaparib).
Arm: Arm E
Participants in Arm E have a history of EBC and have developed ipsilateral locoregional recurrence (the cancer has returned in the same area where the original tumor was).
Arm: Arm F
Participants in Arm F completed treatment for EBC and had breast surgery 5 or more years ago.

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year. ]